



WORLD
CONGRESS
USA

STRATEGY, INVESTMENT, PARTNERING
AND DEAL MAKING FOR LIFE SCIENCE
EXECUTIVE LEADERS

2nd Annual Conference

October 7-8, 2019
Convene Convention Center
Boston, USA

LSX World Congress USA

What is it and who is it for?



The 2nd annual LSX World Congress USA is a high-caliber, senior executive, two-day conference and partnering event providing the education, strategies, solutions and contacts that life science companies need to enable more effective investment, planning and strategic growth within their businesses. The US edition of the World Congress follows on from five previous highly successful congresses following the unique style and format of LSX in London.

Why Attend?

- ① **Understand** the long term trends affecting the industry from industry-leading investment funds, global heads of pharma BD and CEOs of some of the world's most exciting healthcare businesses
- ② **Hear** war stories, advice and key success factors from CEOs who have taken their company through major milestones and who are internationalizing the businesses
- ③ **Participate** in one of our unique, curated, invitation only Chatham House Rule Forums for Investors, Early Stage and Growth Stage Private companies
- ④ **Network** with 200+ life science CxOs, international investors and key partners, convening to address key executive issues facing companies in the sector
- ⑤ **Sign-up** to one or more of four workshops offering practical advice, guidance and outcome orientated content for companies positioning themselves for licensing deals, clinical progress and value based regulatory strategies
- ⑥ **Connect with Purpose** to our community - the life science executives of LSX

Speakers



Alex Bargar
Vice President of
Clinical Services,
Simple Health



Kenneth Barr
SVP, Head of
Discovery Services,
Syngene



Jeff Behrens
President &
CEO, Siamab
Therapeutics



Laura Benjamin
Founder & CEO,
Oncologie



Jeff Berkowitz
CEO & Director,
Real Endpoints



Nicole Bocskocsky
VP of Clinical
Operations,
Parsley Health



Constantine Chinoporos
CBO, Boston
Pharmaceuticals



Sharon Choe
SVP, IR & Business
Development,
LaVoie Health
Science



Alan Crane
Entrepreneur
Partner, Polaris
Partners



David De Graff
CEO, Comet
Therapeutics



Darin De Carlo
Sr Principal &
Segment Lead,
IQVIA



Peter Dudek
Partner, MRL
Ventures Fund



Andrew ElBardissi
Principal,
Deerfield
Management



Neal Farber
CEO,
NeuroHealing
Pharmaceuticals




Melissa Fensterstock
Co-Founder and
CEO, Lansdowne
Labs



Meredith Fisher
Partner, Partners
Healthcare



Mark R. Fitzgerald
Partner, Wilson
Sonsini Goodrich
& Rosati



Todd Foley
Managing Partner,
MPM Capital



Farah Gerdes
Partner,
Technology
Transactions,
Wilson Sonsini
Goodrich & Rosati




John Glasspool
CEO, Anthos
Therapeutics




Alexandra Glücksmann
CEO, Cedilla
Therapeutics



Kelly Gold
VP, Corporate
Development,
CAMP4
Therapeutics



Thomas Goodin
Senior Director,
Clinical
Development,
Sunovion
Pharmaceuticals



Dan Grau
CEO, Sojournix



Adam Houghton
VP & Head,
AbbVie Ventures



Nouhad Hussein
VP, Head of BD,
Regeneron
Pharmaceuticals




Patrick Jordan
CEO, Mycovia



Ed Kaye
CEO, Stoke
Therapeutics



Jeffrey Handwerker
Partner,
Arnold and Porter



Ariane Horn
Partner,
Arnold and Porter

Speakers



Anjali Kumar

External Innovation Search and Evaluation, Eastern United States, Johnson & Johnson Innovation, Boston



Donna LaVoie

President & CEO, LaVoie Health Science



Philippe Lopes-Fernandes

SVP, Global Head of BD & Alliance Management, Merck KGaA




Allan Morgan

Senior Director, IQVIA



Shakti Narayan

CEO, Accent Therapeutics



Aaron Nelson

Principal, Novartis



Joshua Resnick

Managing Partner, RA Capital Management



Veronique Riethuisen

SVP, Global Head of BD & Alliance Management, Ipsen



Priyanka Rohatgi

Managing Director, Head, Ipsen Ventures




Adam Rosenberg

President & CEO, Rodin Therapeutics



Jay Sales

Director, Advanced Technology, VSP Global



Satish Sanan

Chairman and CEO, Inspirata, Inc.



Aradhana Sarin

Chief Strategy & Business Officer, Alexion Pharmaceuticals




Nigel Sheail

Global Head of M&A, Business Development & Licensing, Novartis




James Siestra

CBO & Co-Founder, Totient, Inc.



Laurie Smaldone

MD, CSO, NDA Group



Marshall Smith

Head of Global Healthcare, Goldman Sachs



Ori Solomon

Partner, Corporate Department & Co-chair, Emerging Companies & VC, Morrison Foerster



Paul Spreen

Executive Vice President, IQVIA



Laura Tadvalkar

Principal, MP Healthcare Venture Management



Ted Tanner Jr.

CTO and Chief Architect, Watson Health, IBM



Christopher Stepanian

CEO, WindGap Medical



Derek Stoldt

Co-head, M&A & Life Sciences Transactions Practice, Arnold & Porter



Ricky Sun

Partner, Life Sciences, Bain Capital



Ailis Tweed-Kent

CEO, Cocoon Biotech




Rogerio Vivaldi

CEO, Sigilon Therapeutics



Anne Whitaker

CEO & Director, Dance Biopharm



Carolyn Witte

Co-Founder and CEO, Tia

Agenda at a glance

Forum - 7th October

12:00	Registration and Networking Lunch	
13:00	Start-up / Early Stage CEO Forum	Growth / Late Growth Stage CEO Forum
15:00/15	Networking Break	
15:30/45	Start-up / Early Stage CEO Forum	Growth / Late Growth Stage CEO Forum
18:00	CEO Drinks & Dinner	

Conference - 8th October

9:00	Keynote Plenary				1-2-1 Meetings
10:40	Networking Break				
11:10	Main Plenary	Pharma BD Forum	Licensing & Collaboration Workshop	Clinical Strategies Workshop	1-2-1 Meetings
12:50	Networking Lunch				
13:50	Main Plenary	Pharma BD Forum		Value Based Pricing & Contracting Workshop	1-2-1 Meetings
15:30	Networking Break				
16:00	Keynote Plenary				1-2-1 Meetings
17:20	Close of Conference				

Forum Day - October 7th

12:00

Registration and Networking Lunch

Choose from 2x CEO Forums for private early stage and private growth / late growth stage executives to uncover KSFs relating to your company stage.

13:00



Hosted by



A unique, powerful and valuable space for the candid sharing of experience between 20-30 of the sector's pre-series A life science executives. A pre-registration only, exclusive hollow square forum where all participants are active discussants.

*Session Moderator: **Paul Sagan**, Assistant VP, Investor Relations and Corporate Communications, **LaVoie Health Science***

13:00 - Intro from moderator, hosts and 60sec elevator pitch from all executives in the room

*13:15 - Case study: non-dilutive funding to advance R&D
Jeff Behrens, President & CEO, **Siamab Therapeutics***

13:30 - Q&A

*13:45 - Case study: anatomy of a first round financing
Mark R. Fitzgerald, Partner, **Wilson Sonsini Goodrich & Rosati** + **James Siestra**, Co-founder, **Totient Inc.***

14:30 - Q&A

*14:45 - Case Study: International Investment and Company Building: Oncologie A + B with Asian investment partners
Laura Benjamin, Founder & CEO, **Oncologie***

15:00 - Q&A

15:15 - Afternoon Break

*Session Moderator: **Sharon Choe**, SVP, IR and Business Development, **LaVoie Health Science***

*15:45 - Presentation: how to create your life science company presentation in just 15 slides
Donna LaVoie, President & CEO, **LaVoie Health Science***

16:15 - Q&A

*16:30 - Case study: following an asset centric approach to growing your business
Arthur Hiller, CEO, **Antyllus Therapeutics, Inc.***

16:45 - Q&A

*17:00 - Case study: early-stage partnerships to launch and grow your business
Christopher Stepanian, CEO, **WindGap Medical***

17:15 - Q&A

*17:30 - General macro challenge discussion not restricted to valuation, alternative growth strategies and research partnerships
Executives will have the opportunity to highlight areas of interest prior to the afternoon break to aggregate themes for this 30mins session.*

*18:00 - **Networking Drinks followed by CEO Dinner**
Delegates will be directed to the venue at 18:00*

Forum Day - October 7th

13:00

Hosted by



A unique, powerful and valuable space for the candid sharing of experience between 20-30 of the sector's post-series A life science executives. A pre-registration only, exclusive hollow square forum where all participants are active discussants.

Session Moderator: **John Hodgson**, Director, **PersComm Ltd.**

13:00 - Intro from moderator, hosts and 60sec elevator pitch from all executives in the room

13:15 - Case study: challenges in securing later stage investment
Dan Grau, CEO, **Sojournix**

13:30 - Q&A

13:45 - Case study: legal and business challenges in securing late stage financing
Ori Solomon, Partner, Corporate Department and Co-chair, Emerging Companies and Venture Capital, **Morrison Foerster**

14:00 - Q&A

14:15 - Case study: Considerations for a commercialization model: how to optimize value to patients and stakeholders
Allan Morgan, Senior Director, **IQVIA** & **Anne Whitaker**, CEO and Director, **Dance Biopharm**

14:45 - Q&A

15:00 - **Afternoon Break**

15:30 - Case study: Taking your products through the clinic / clinical / R&D strategies
Adam Rosenberg, CEO, **Rodin Therapeutics**

15:45 - Q&A

16:00 - Case study: finding new directions for success after clinical failures
Neal Farber, CEO, **NeuroHealing Pharmaceuticals**

16:15 - Q&A

16:30 - Case study: M&A as a strategic multiplier
Satish Sanan, Chairman and CEO, **Inspirata, Inc.**

16:45 - Q&A

17:00 - Case study: preparing commercial go-to-market, strategies and activities
John Glasspool, CEO, **Anthos Therapeutics**

17:15 - Q&A

17:30 - Plus General macro challenge discussion not restricted to valuations and dilutions, research partnerships, market access, pricing and exit dynamics
Executives will have the opportunity to highlight areas of interest prior to the afternoon break to aggregate themes for this 30mins session.

18:00 - **Networking Drinks followed by CEO Dinner**
Delegates will be directed to the venue at 18:00

Conference Day - October 8th

8:00

Registration and Breakfast

9:00


**PLENARY
SESSIONS**
KEYNOTE PRESENTATION: CAPITAL MARKETS OUTLOOK
Marshall Smith, Head of Global Healthcare, Goldman Sachs

9:20


**PLENARY
SESSIONS**
INVESTOR PANEL: MACRO TRENDS, MARKET CORRECTIONS AND UNMET MEDICAL NEED

What are the factors currently fuelling VC and public markets, how are these affecting the entrepreneurial scene and more well established firms and how do executives see these impacting appetite and strategies for investing and company building? Plus, with prominent reloads, what areas are grabbing investor's attention?

Moderator: **Paul Spreen**, EVP and Chief Customer Officer, **IQVIA**

Todd Foley, Managing Partner, **MPM Capital**

Ricky Sun, Partner, Life Sciences, **Bain Capital**

Meredith Fisher, Partner, **Partners Healthcare**

Alan Crane, Entrepreneur Partner, **Polaris Partners**

Joshua Resnick, Managing Partner, **RA Capital Management**

10:00


**PLENARY
SESSIONS**
PHARMA PANEL: STRATEGIC SHIFTS IN ADDRESSING PIPELINE DRIFT; PHARMA M&A AND PARTNERING IN 2020

Notwithstanding the legacy factors continuing to influence strong deal flow, how is Pharma responding to the emerging encroachment of tech giants into their territories? Does this present co-operation opportunities or unwelcome competition and how will this impact external M&A, partnering and consolidation strategies?

Moderator: **Jerry Lee**, Managing Director, **Goldman Sachs**

Veronique Riethuisen, SVP, Global Head of Business Development & Alliance Management, **Ipsen**

Philippe Lopes-Fernandes, SVP, Global Head of BD & Alliance Management, **Merck KGaA**

Nigel Sheail, Global Head of Mergers & Acquisitions and Business Development & Licensing, **Novartis**

Aradhana Sarin, Chief Strategy & Business Officer, **Alexion Pharmaceuticals**

10:40

Networking Break

11:10


**PLENARY
SESSIONS**
CORPORATE INVESTOR PANEL: NOTHING VENTURED, NOTHING GAINED; BACKING BIGGER ROUNDS AND MAKING BIGGER BETS

With the size of the average investment rounds getting bigger across the entire venture industry how are CVCs aligning with this trend? What can we expect to see from CVCs in terms of leading investment rounds and how is the macro environment affecting the approaches CVCs are taking. Plus, executives share some insights into their current investment preferences.

Moderator: **Derek Stoldt**, Co-Head, M&A and Life Sciences Transactions Practice, **Arnold & Porter**

Peter Dudek, Partner, **MRL Ventures Fund**

Priyanka Rohatgi, Managing Director, Head, **Ipsen Ventures**

Aaron Nelson, Principal, **Novartis Venture Fund**

Adam Houghton, Vice President and Head, **AbbVie Ventures**

Laura Tadvalkar, Principal, **MP Healthcare Venture Management (MPH)**

11:50


**PLENARY
SESSIONS**
EXECUTIVE PANEL: RAISING THE BAR; MAKING THE 'SERIES' A GRADE

In an industry becoming increasingly defined by weighty Series A's, executives who have been instrumental in achieving incredible early-stage venture raises share their success stories and war stories in equal measure. Plus, share what we can expect to see from their companies as they continue to deploy their capital.

Moderator: **Ori Solomon**, Partner, Corporate Department and Co-chair, Emerging Companies and Venture Capital, **Morrison Foerster**

David De Graaf, CEO, **Comet Therapeutics**

Michael Pavia, CEO, **Tuned Therapeutics**

Andrew ElBardissi, Principal, **Deerfield Management**

Alexandra Glücksmann, CEO, **Cedilla Therapeutics**

12:30


**PLENARY
SESSIONS**
PRESENTATION: LEVERAGING STRATEGIC PARTNERSHIPS TO ACCELERATE THE PROGRESS OF YOUR MOLECULE(S)
Kenneth Barr, SVP, Head of Discovery Services, **Syngene**

Conference Day - October 8th

12:50

Networking Lunch

13:50



PLENARY SESSIONS

EXECUTIVE PANEL: DE-RISKING THE REGULATORY APPROVAL PATH - HOW TO OPTIMIZE YOUR INVESTMENT DOLLARS

The path to global product approval is notorious for hurdles from every angle; from technical/scientific risk to regulatory and market access risk. The hurdles are even more evident when there is limited or no precedent for the indication being sought that could impact time, cost and approvability. Executives explore the best ways to minimize these risks and probe cases that address these issues during development, sharing de-risking strategies for keep innovative programs on track.

Moderator: **Laurie Smaldone Alsup, MD, CSO, NDA Group**

Ed Kaye, CEO, Stoke Therapeutics

Ailis Tweed-Kent, CEO, Cocoon Biotech

John Glasspool, CEO, Anthos Therapeutics

Christine Swenson, Head, Regulatory Affairs, Moderna Therapeutics

14:30



PLENARY SESSIONS

PARTNERING WITH J&J: THE WHY, HOW AND WHAT

Anjali Kumar, External Innovation Search and Evaluation, Eastern United States, Johnson & Johnson Innovation, Boston

14:50



FIRESIDE CHAT

KEYNOTE CHAT: THE RATIONALE OF AI IN HEALTHCARE? IT'S HUMAN NATURE

Ted Tanner Jr., CTO and Chief Architect, Watson Health, IBM

Jay Sales, Director, Advanced Technology, VSP Global

15:10



PLENARY SESSIONS

PRESENTATION: COMMERCIALIZATION: ALTERNATIVE TO A TRADITIONAL EXIT PLAN

The importance of a robust development and commercialization strategy has never been more evident. This presentation will outline the considerations needed as your drug progresses through the developmental phases towards the market and share advice on how to minimize the risk that your company's therapy will end up a commercial failure.

Darin DeCarlo, Senior Principal and Segment Lead, IQVIA

15:30

Networking Break

16:00



PLENARY SESSIONS

EXECUTIVE PANEL: MOVERS, SHAKERS AND THERAPEUTIC DEAL MAKERS

With lofty biotech valuations and rising competition in key therapeutic fields, executives who have positioned their companies as attractive for deal making opportunities share their experiences, KSFs and fundamentals when engaging big pharm. Plus executives share what we can expect to see from their respective companies in the year ahead.

Moderator: **Farah Gerdes, Partner, Technology Transactions, Wilson Sonsini Goodrich & Rosati**

Rogerio Vivaldi, CEO, Sigilon Therapeutics

Kelly Gold, Vice President, Corporate Development, CAMP4 Therapeutics

Nouhad Hussein, Vice President, Head of Business Development, Regeneron Pharmaceuticals

Constantine Chinoporos, CBO, Boston Pharmaceuticals

16:40



PLENARY SESSIONS

CLOSING PANEL: KNOCKING ON THE DOOR; THE BOOMING DIRECT-TO-CONSUMER (D2C) HEALTHCARE MODEL

With tech players increasingly encroaching in healthcare, forcing companies — as well as startups — to think of different ways to reach patients, and investors wagering that consumers will be increasingly willing to shop for healthcare the same way they buy more traditional products online, what can we expect from the D2C model?

Moderator: **John Hodgson, Director, PersComm Ltd.**

Alex Bargar, VP Clinical Services, Simple Health

Melissa Fensterstock, Co-Founder and CEO, Lansdowne Labs

Carolyn Witte, Co-Founder and CEO, Tia

Nicole Bocskocsky, VP of Clinical Operations, Parsley Health

17:20

Close of Congress

Conference Day - October 8th

Satellite Forums

11:00



Pharma BD Forum is a high profile forum designed primarily for global and regional BD heads from the larger and mid cap (>\$1bn) Pharma and Biotech companies, and key influential partners and stakeholders in the sector.

The forum will address the key industry challenges head on, providing genuine outcomes for the executives and the sector as a whole. **This is an invite-only forum and not open to general attendees.**

Location: South Boardroom



1-2-1 partnering will take place in a dedicated room with private meeting tables and 30min allocated slots.

8 hours of enabled partnering outside of the informal networking during breaks will be scheduled from approx. 8.30am - 5pm on the 8th October.

Location: The Hub East



The clinical strategies workshop is a 1.5hr intimate, interactive forum in which a leading CRO partner hosts an intimate group of CxOs who are transitioning into clinical development and interested in exploring business models and approaches to partnerships in clinical trials.

Panel: Clinical Strategies Workshop: Capturing the attention of investors

Michael Kardas, Vice President, Strategic Drug Development, IQVIA
Patrick Jordan, CEO, Mycovia
Thomas Goodin, Senior Director, Clinical Development, Sunovion Pharmaceuticals Inc.

This is a unique opportunity for candid sharing of experiences with an intimate group of biopharma executives transitioning into clinical development. The session includes:

- Discussion of the key elements of long term strategic planning that enables you to articulate a compelling value to investors.
- Panel discussion with biopharma executives
- Q&A session

Location: The Hub West



The Licensing & Collaboration Workshop is a 1.5hr intimate, interactive forum in which CEOs and CBOs navigate the how, what, where and when of a successful licensing deal / strategic collaboration.

Delivering strategy, tactics, mechanics and ideas.

Licensing & Collaboration Deals: Trends and Drivers

Farah Gerdes, Partner, Technology Transactions, Wilson Sonsini Goodrich & Rosati

- Why collaborate?
- Market Trends & Drivers
- Traditional drivers
- Early stage vs. Late Stage
- Deal elements that drive value
- Beyond the NCE – subject matter/technology being licensed
- The changing the face of collaborations:
- Technology
- Big Data
- Open innovation

Case study of a successful licensing deal
Shakti Narayan, CEO, Accent Therapeutics

Key Considerations in Licensing & Collaboration Deals

The Collaboration Lifecycle, Key terms, Scope, Governance, Financials, IP, Exit, Impact of trends on deal terms and Future-proofing the deal

Location: The Library

12:50

Networking Lunch

Conference Day - October 8th

Satellite Forums cont.

12:50

Networking Lunch

13:50



Pharma BD Forum is a high profile forum designed primarily for global and regional BD heads from the larger and mid cap (>\$1bn) Pharma and Biotech companies, and key influential partners and stakeholders in the sector.

The forum will address the key industry challenges head on, providing genuine outcomes for the executives and the sector as a whole. **This is an invite-only forum and not open to general attendees.**

Location: South Boardroom



1-2-1 partnering will take place in a dedicated room with private meeting tables and 30min allocated slots.

8 hours of enabled partnering outside of the informal networking during breaks will be scheduled from approx. 8.30am - 5pm on the 8th October.

Location: The Hub East



The value-based pricing and contracting workshop is a 1.5hr intimate, interactive forum for CEOs who are implementing value-based strategies in order to meet the needs of the patients, payers and regulators.

Workshop Leaders

Jeffrey Handwerker, Partner, **Arnold & Porter**
Ariane Horn, Partner, **Arnold & Porter**

13.50 Overview of Value-Based Strategies

- What is a Value-Based Arrangement?
- Why Value-Based Arrangements Are of Interest to Manufacturers, Payers, State
- Agencies and other Stakeholders?
- Types of Agreements
- Key Legal Considerations
 - Anti-Kickback Statute
 - Drug Price Reporting
 - Off-Label Promotion
 - Privacy
 - Government Transparency

14.30 Business Perspectives on Value-Based Strategies

- **Jeff Berkowitz**, CEO and Director, **Real Endpoints**

14.50 Case Studies / Panel Discussion

- Payer rebates based on adherence measures
- Payer rebates based on failure to achieve pre-specified efficacy measures
- Payer rebates based on total costs of care for patients on one drug versus patients on different drugs
- Hospital delayed payment pending achievement of pre-specified efficacy measures

Location: The Hub West

15:30

Networking Break

Our Partners

Platinum Partners



Gold Partners



Silver Partner



Supporting Partners



Media Partners



Confirmed 2019 Attendees

Managing Director & Founder, 37celsius
Head of East Coast Business Development & Acquisitions, Abbvie
VP & Head, AbbVie Ventures
Venture Partner, Abingworth
Operating Partner, Accelmed
CEO, Accent Therapeutics
Chairman & CEO, ACS Global
(American CryoStem Corporation)
Head of Business Development for USA, AdlaiNortye USA Inc
Managing Partner, Alacrita
Senior Consultant, Alacrita
President & Founder, Alertgy Inc
Corporate Strategy & Business Development, Alexion Pharmaceuticals
SVP, Head of Business Development & Strategy, Alexion Pharmaceuticals, Inc.
Sr. VP, Allied Minds
COO, American Cryosystem
CEO, AMRA Medical
VP of Strategic Alliances & Licensing, Amryt Pharma
CEO, Anthos Therapeutics
CEO, Antidote.me
CEO, Antyllus Therapeutics
President & CEO, Aqua Medical, Inc.
Partner, Arnold & Porter
Partner, Arnold & Porter
Partner, Arnold & Porter
Partner, Arnold & Porter
Partner, Arnold & Porter
VP, Corporate Strategy & Development, AstraZeneca
CEO & Co-Founder, Astrocyte Pharmaceuticals Inc.
Managing Director, AUGC
Chief Executive Officer and Managing partner, Back Bay Life Science Advisors
Principal, Bain Capital
Head of Global Business Development, Licensing and Specialty Medicine, Bayer Healthcare Pharmaceuticals
Associate Editor, BioCentury Publications
Founding Partner, BOHE Angel Fund
CBO, Boston Pharmaceuticals
Senior Director, Asset Acquisition, Bridge Bio
Associate, Broadview Ventures
Associate, Broadview Ventures
Principal, Broadview Ventures
President & CEO, Caladrius Biosciences
VP, Investor Relations & Corporate Communications, Caladrius Biosciences
President, Cambridge BioPartners
CEO, CAMP4 Therapeutics
VP Corporate Development, CAMP4 Therapeutics

Associate Director Business Development, CAMP4 Therapeutics
Principal, Capital Family Office
CEO & Co-Founder, Cardiomo Care
CTO, Cardiomo Care
Head of Practice - Pharmaceutical & Biotech EMEA, Carmichael Fisher Executive Search
President & CEO, Cedilla Therapeutics
Chief Executive Officer, Cereno Scientific AB
Chairman of the Board & CEO, ChemioCare
Life Tech Industry Manager, City of Boston
Director of Economic Development, City of Cambridge
Senior Economic Development Manager, City of Cambridge
Co-Founder & Managing Director, Co-D Therapeutics, Inc.
Executive Chairman, Co-D Therapeutics, Inc.
Founder & CEO, Cocoon Biotech
CBO, Codiak Biosciences
CEO, Comet Therapeutics
Director of Business Development, Corbus Pharmaceuticals Inc
Managing Director Healthcare Investments, Cowen Healthcare Investments
Partner, Cure Ventures
Project Leader: Precision Medicine Initiative, CVB
CEO, Dance Biopharm
Principal, Deerfield
CEO, Drop Genie
CEO, Dualogics LLC
Managing Director, EGB Ventures
Director, Eikonizo Therapeutics
CEO, Eikonizo Therapeutics
CEO, Elsius Biomedical
Owner, enERGetics Biopharmaceutical
Chief Operating and Chief Business Officer, EpimAb Biotherapeutics Inc.
CEO, ethris GmbH
Director of Business Development, North America, Euretos
Senior Director, Business Development, Evotec
Director BD, Fortress Biotech
Director of Business Development, FreeMind Group
Partner, Freshfields Bruckhaus Deringer
Partner, Freshfields Bruckhaus Deringer
Counsel, Freshfields Bruckhaus Deringer
Partner, Freshfields Bruckhaus Deringer
Director, FTI Consulting
Senior Managing Director, FTI Consulting, Inc
Managing Director, GE Ventures
Managing Director, Goldman Sachs
Head of Global Healthcare, Goldman Sachs
Head of Healthcare Banking EMEA, Goldman Sachs

Confirmed 2019 Attendees

Executive Vice President & Chief Business Officer
Corporate Strategy and Business Development, H.
Lundbeck
COO, Haima Therapeutics LLC
Partner, HealthCare Royalty Partners
CEO, HemoGenyx Pharmaceuticals plc
Managing Director of Life Sciences, Hercules
Capital
CEO, HoloBiome
Managing Director, Horizon Technology Finance
CTO, IBM
Executive Vice President Chief Business Officer,
ImmunSYS Inc.
Chief Financial Officer, ImmunSYS, Inc.
CEO & President, Inanovate Inc
EVP Medicines Access, Inceptua Group
VP Consulting, Inceptua Medicines Access
Editor, InnoHealth
CFO, Insigntra Medical
Chairman & CEO, Inspirata, Inc.
CEO, Intrommune Therapeutics
Co-Founder & CSO, Intrommune Therapeutics
SVP, Global BD & Alliance Management, Ipsen
Managing Director, Ipsen Ventures
Marketing, IQVIA
US Tech Solutions, National Emerging BioPharma
Strategy Lead and Mid-Atlantic Regional GM, IQVIA
Director, Emerging Biopharma Solutions, IQVIA
Senior Director, IQVIA
Innovation Vice President, Design & Delivery, IQVIA
EVP and Chief Customer Officer, IQVIA
Sr Principal and Segment Lead, IQVIA
Alliance Manager, IQVIA
VP & GM Strategy and Portfolio Planning, IQVIA
R&D Solutions Business Development, IQVIA
Director, Account Management, IQVIA
CTO, Javelin Biotech
CEO, Javelin Biotech
Investment Professional, JDRF T1D Fund
External Innovation Search and Evaluation, Eastern
United States, Johnson & Johnson
Chairman & General Partner, Julz Co LLC
Director, Julz Co LLC
CFO, Karuna Therapeutics
Founder, kronos.vc
CEO, Lansdowne Labs
President & CEO, LaVoieHealthScience
AVP, Investor Relations and Corporate
Communications, LaVoieHealthScience
SVP, IR & Business Development,
LaVoieHealthScience
Head of Investments, Longevity Vision Fund

Venture Partner, Longevity Vision Fund
President & CEO, Luminary Therapeutics
VP Business Development, Luminary Therapeutics
Vice President & General Manager, LuxMed
Systems, Inc.
CEO, LuxMed Systems, Inc.
Founder, Maidstone Life Sciences
CFO, Massachusetts Life Sciences Center
Associate Director Business Development,
Massachusetts Life Sciences Center
VP Marketing & Communications, Massachusetts
Life Sciences Center
VP of Industry Programs & Relations,
Massachusetts Life Sciences Center
Director of Business Development, Massachusetts
Life Sciences Center
President & CEO, MedWaves, Inc.
Associate Vice President and Head of Boston
Innovation Hub, BD&L, Merck
SVP & Global Head of Business Development &
Alliance Management, Merck KGaA
CFO, Minovia Therapeutics
VP Chemistry, Mitobridge
Head, Regulatory Affairs, Moderna Therapeutics
COO, Morgan Prestwich
Partner, Morrison & Foerster LLP
Partner, Morrison Foerster
CEO, Mount Tam Biotechnologies
Principal, MP Healthcare Venture Manage
Managing Director, MPM Capital
Partner, MRL Venture Fund
Partner, MVM Life Science Partners LLP
CEO, Mycovia
SVP, Commercialization, Mycovia Pharmaceuticals,
Inc.
CEO, NDA Group
Director, Business Development, NDA Group
CSO, NDA Group
CEO, NeuroHealing Pharmaceuticals, Inc.
CEO, retired, North Shore InnoVentures
Head of BD&L, Novartis
Principal, Novartis Venture Funds
Founder & CEO, Oncologie, Inc
CDO, Oncologie, Inc
CEO & Co-Founder, Oscine Therapeutics
CEO, Panorama Medicine
VP of Clinical Operations, Parsley Health
Partner, Partners Healthcare
President, PBM Capital
Director, PersComm Ltd.
President & CEO, Personal Remedies LLC
SVP Worldwide Business Development, Pfizer

Confirmed 2019 Attendees

VP, Head of R&D, PIC Therapeutics
CEO, PIC Therapeutics
Biology Professional, PIC Therapeutics
Partner, Pillar VC
Partner, Polaris Partners
CEO, PurpleSun
Managing Director, RA Capital Management
CEO & Director, Real Endpoints
VP & Head of Business Development, Regeneron Pharmaceuticals Inc
CEO, Repair Biotechnologies
Principal Scientist, Repair Biotechnologies
CEO, Resolute.ai
CTO, Resolute.AI
CEO, Rinri Therapeutics
CEO, President, Co-Founder, Riparian Pharma
CFO, Rodin Therapeutics
President & CEO, Rodin Therapeutics Inc
Head of M&A, Sanofi
EVP, Strategy & Business Development, Sanofi
CEO, SciBac Inc.
Founder, Sen-Jam Pharmaceutical
CEO, Sen-Jam Pharmaceuticals
President & CEO, Siamab Therapeutics
CBO, Sigilon
President & Chief Executive Officer, Sigilon Therapeutics
Director of Business Development, Sigilon Therapeutics
CEO, Sigilon Therapeutics
VP of Clinical Services, Simple Health
Investor, Sky Ventures
President, CEO & Director, Sojournix
CTO, Solid Bio
CEO, Solid Biosciences Inc
CFO, Sorrento Therapeutics Inc
CEO, Spring Bank Pharmaceuticals Inc
Founder & Managing Director, Springhood Ventures LLC
Product & Business officer, sRNAlytics
CEO, Stoke Therapeutics Inc
Senior Director, Clinical Development, Sunovion Pharmaceuticals Inc.
Operating Partner, Sweetwater Capital Partners
Co Founder, Chairman of the Board, President & Chief Executive Officer, SynDevRx
Co-Founder & VP of Business Development, SynDevRx
SVP, Head of Discovery Services, Syngene
Head of Marketing, Syngene International
Business development, Syngene international
Lead- Discovery Services, Syngene International

CCO, Syngene International Ltd
CEO, Tactical Therapeutics
Global Business Development Officer, Takeda Pharmaceutical Company
President & CEO, Therapeutic Vision Inc
CEO & Co-Founder, Tia
CBO & Co-Founder, Totient Inc.
Partner, TransPacific Venture Capital Partners
CEO, Tuned Therapeutics
Director, Advanced Technology, VSP Global
Partner, Wilson Sonsini Goodrich & Rosati
Partner, Wilson Sonsini Goodrich & Rosati
Partner, Wilson Sonsini Goodrich & Rosati
CEO, Windgap Medical, Inc.
Co-Founder, President & CEO, X-Biotix Therapeutics Inc
Executive Advisor of Business Development, X-Chem
Fellow, Yale

Delegate packages

Corporate Standard 1-day Ticket*

- Access to early partnering 7th Oct
- **Access to 1 of 3 suitable CEO Forums 7th Oct (life science CEOs only)**
- Access to drinks reception 7th Oct
- **Access CEO VIP dinner 7th Oct**

OR

- Access to conference day 8th Oct
- Access to conference workshops 8th Oct
- Access to 1-2-1 partnering portal
- Access to drinks reception 8th Oct

~~Until 19 July 19 -- \$795 / \$595~~
~~Until 09 Aug 19 -- \$895 / \$695~~
~~Until 30 Aug 19 -- \$995 / \$795~~
~~Until 20 Sept 19 -- \$1,195 / \$995~~
Full Price - \$1,395 / \$1,195

* Biotech / Medtech / Healthtech / Pharma / Big Tech company executives only

Services 1-day Ticket***

- Access to conference day 8th Oct
- Access to 1-2-1 partnering portal
- Access to drinks reception 8th Oct

~~Until 19 July 19 -- \$895~~
~~Until 09 Aug 19 -- \$995~~
~~Until 30 Aug 19 -- \$1,145~~
~~Until 20 Sept 19 -- \$1,295~~
Full Price - \$1,445

*** Financial / Professional / Contract Services

Corporate VIP 2-day Ticket*

- Access to early partnering 7th Oct
- **Access to 1 of 3 suitable CEO Forums 7th Oct (life science CEOs only)**
- Access to drinks reception 7th Oct
- **Access CEO VIP dinner 7th Oct**
- Access to conference day 8th Oct
- Access to conference workshops 8th Oct
- Access to 1-2-1 partnering portal
- Access to drinks reception 8th Oct

~~Until 19 July 19 -- \$1,345~~
~~Until 09 Aug 19 -- \$1,495~~
~~Until 30 Aug 19 -- \$1,645~~
~~Until 20 Sept 19 -- \$1,795~~
Full Price - \$1,945

* Biotech / Medtech / Healthtech / Pharma / Big Tech company executives only

Investor VIP 2-day Ticket**

- Access to early partnering 7th Oct
- **Access to Investor Forum 7th Oct**
- Access to drinks reception 7th Oct
- **Access Investor VIP dinner 7th Oct**
- Access to conference day 8th Oct
- Access to conference workshops 8th Oct
- Access to 1-2-1 partnering portal
- Access to Investor VIP lounge
- Access to drinks reception 8th Oct

~~Until 19 July 19 -- \$345~~
~~Until 09 Aug 19 -- \$395~~
~~Until 30 Aug 19 -- \$445~~
~~Until 20 Sept 19 -- \$495~~
Full Price - \$595

** Qualified investors only

Register online at www.lsxleaders.com/usa

If you have any questions please contact: joe@lsxleaders.com, +44 (0) 203 637 5908

Industry Leading Events for the Life Science C-Suite



**WORLD
CONGRESS
USA**

7-8 October 2019
Convene Convention Center, Boston, USA
www.lsxleaders.com/usa



**DIGIHEALTH
LEADERS**

13-14 November 2019
The Crystal, Royal Victoria Dock, London, UK
www.lsxleaders.com/digihealth

INVESTIVAL SHOWCASE™
CONNECTING LIFE SCIENCE & HEALTHCARE COMPANIES WITH CAPITAL

19 November 2019
The Hilton Waldorf, London, UK
www.lsxleaders.com/investival



19 November 2019
The Honourable Artillery Company, London, UK
www.lsxleaders.com/lifestars



**WORLD
CONGRESS**

4-5 February 2020
etc. venues, 133 Houndsditch, London, UK
www.lsxleaders.com/london



**LONGEVITY
LEADERS**

21-22 April 2020
etc. venues, 133 Houndsditch, London, UK
www.longevityleaders.com




**NORDIC
CONGRESS**

2-3 September 2020
Nasdaq Offices, Stockholm, Sweden
www.lsxleaders.com/nordic

Contact us today to find out how to get involved in any or all of our events.

www.lsxleaders.com/events

Conference Floorplan



Onsite Team




Neil Darkes
Co-CEO



Terry O'Dwyer
Co-CEO



Josh Dance
SVP, Production



Matthew Pullan
SVP, BD



Brooke Roberts
Head of VIP
Networking
(1:1 Meetings)



Rebecca Herne
Head of
Operations
(Registration)

Contact Us

For speaker opportunities contact:

Josh Dance, SVP
josh@lsxleaders.com
+44 (0) 203 637 5908

For sponsor opportunities contact:

Matt Pullan, SVP, BD & Partnerships
matt@lsxleaders.com
+44 (0) 203 637 5908

For bookings contact:

Joseph Knight, BD Manager
joe@lsxleaders.com
+44 (0) 203 637 5908

Or visit us at
www.lsxleaders.com/usa